AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Wiz acquires Dazz for $450 million to strengthen AI-driven cloud security
2
Cyera doubles valuation to $3B with $300M Series D, total funding hits $600M in seven months
3
Claroty veterans launch Twine with $12M in Seed funding from Dell and Wiz founders to deploy AI cyber workers
4
Mediaocean acquires Innovid for $500M, delisting it from the NYSE
5
Prompt Security raises $18 million Series A to protect enterprises from GenAI risks
More news

Teva

20 stories about Teva
קור שולץ מנכ"ל טבע 9.11.19

Teva Announces $1.5 Billion Debt Tender Offer

10.11.19|Sophie Shulman
On Thursday, the Israeli drugmaker published its third quarter reports for 2019, reporting it had cut down its net debt to $25.7 billion
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva Quarterly Report Meets Analyst Expectations

07.11.19|Sophie Shulman
The Israeli drugmaker’s revenues dropped 6% in the third quarter of 2019 to $4.26 billion. Debt dropped by $1.8 billion to $26.9 billion
מטה חברת טבע תרופות

Teva Overcomes One Hurdle, Many Still Ahead

23.10.19|Hezi Sternlicht
The Israeli drugmaker announced on Monday two major achievements regarding the opioid abuse lawsuits against it; but even without taking into consideration its additional legal complications, the settlements it has reached will severely strain its resources
מטה חברת טבע תרופות

Teva Announces $23.25 Billion Opioid Abuse Settlement Agreement

22.10.19|Lilach Baumer
Teva announced on Monday a settlement with both Cuyahoga and Summit counties of Ohio, averting the trial scheduled for later that day, and an agreement in principle for a global settlement framework
מטה חברת טבע תרופות

Teva Consortium Fails to Reach Opioid Abuse Settlement, Report Says

20.10.19|CTech
A $50 billion offer made last week by Teva and the three largest drug distributors in the U.S. does not seem to have panned out, Reuters reported Friday
מטה חברת טבע תרופות

Teva Part of $50 Billion Opioid Settlement Deal, Report Says

17.10.19|Hezi Sternlicht
Teva, a second drugmaker, and the three largest drug distributors in the U.S. have agreed with multiple states on a settlement framework ahead of Monday’s trial, the New York Times reported Thursday
אתר טבע כפר סבא

Teva Makes $15 Billion Settlement Offer in U.S. Opioid Case, Report Says

16.10.19|Hezi Sternlicht
The Israeli drugmaker and several other drug distributors are set to face around 2,500 lawsuits related to the U.S. opioid abuse epidemic in just a week at a Cleveland, Ohio federal court
מטה חברת טבע תרופות

Judge Rejects Teva’s Request to Be Tried Separately in U.S. Opioid Case, Report Says

13.10.19|CTech
Teva made a last minute attempt to be tried separately in opioid abuse damages case set to be held on October 21 in federal court in Cleveland, Ohio
מטה חברת טבע תרופות

Teva Part of Consortium Looking to Participate in Purdue Pharma's Bankruptcy, Report Says

02.10.19|CTech
Five of the drugmakers currently battling opioid abuse damages lawsuits in the U.S. are looking to achieve a global settlement through Purdue's bankruptcy case, the Wall Street Journal reported Monday
רון מירון מנכ"ל חברת אייסיקיור

Cannabis Company InnoCan Lists on the Canadian Securities Exchange

26.09.19|Tzally Greenberg
The Israel-based company listed 4% of its shares and raised $1.5 million at a $12.08 million company valuation
חברת תרופות אלרגן

Allergan Says Teva Bears Sole Liability for Actavis' Actions

02.09.19|Hezi Sternlicht
Actavis, which Teva bought from Allergan in 2016 for $40.5 billion, was one of the top U.S. sellers of opioids in 2006-2012
אתר טבע כפר סבא

Teva to Close Missouri Plant, Report Says

29.08.19|Tzally Greenberg
Teva’s manufacturing plant in Israeli city Netanya is also slated for final closure in early 2020, as part of the company’s reorganization plan
מטה חברת טבע תרופות

Teva Crashes Following Purdue Pharma $10-$12 Billion Settlement Reports

28.08.19|Lilach Baumer
Teva, like many other opioid manufacturers operating in the U.S., will be facing multiple opioid abuse-related lawsuits at a trial set to start in October at an Ohio federal court
אתר טבע כפר סבא

Teva Faces New Opioid-Related Lawsuit in West Virginia

25.08.19|Hezi Sternlicht
The lawsuit seems to be unrelated to the trial set to start against Teva and other opioid manufacturers in October in Ohio federal court
מטה חברת טבע תרופות

Teva Jumps on NYSE on a Bit of Good News

21.08.19|Hezi Sternlicht
An opioid-abuse lawsuit settlement reached by drugmakers Endo and Allergan Tuesday could bode well for Teva’s legal future, as does the release of an FDA-approved generic version of EpiPen JR
default image

Senior Teva R&D Executive Joins Cannabis Company Cannassure

18.08.19|Tzally Greenberg
Yafit Stark was responsible for Teva’s clinical development program during the development of flagship drug Copaxone
מטה חברת טבע תרופות

Despite Losses, Teva Pays Employee Bonuses for 2018

13.08.19|Hezi Sternlicht
Though Teva ended 2018 with a net loss of over $2.45 billion, the company awarded its employees with bonuses worth $390 million for the fiscal year’s results
מפעל תרופות טבע

Credit Line and Bonds: Teva's Financial Catch

12.08.19|Uri Tal-Tene
At first glance, Teva’s second quarter reports provided little cause for drama. The small print reveals a very different story
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva Beat Analysts’ Consensus, But Its Big Battles Are Still Up Ahead

08.08.19|Sophie Shulman
Teva ends the second quarter of 2019 down a CFO, with negative cash flow and the threat of lawsuits that could cost billions. In his call with analysts, CEO Kare Schultz hinted at the possibility of future layoffs, but Teva still handed out $240 million worth of annual bonuses to senior executives
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva Beats Analysts on Second Quarter Operating Income, Revenues

07.08.19|CTech
The company also announced chief financial officer Michael McClellan will be stepping down after two years for personal reasons related to family
Previous ArticlesMore Articles